Provided by Tiger Fintech (Singapore) Pte. Ltd.

Contineum Therapeutics, INC.

6.86
-0.2000-2.83%
Volume:100.70K
Turnover:709.90K
Market Cap:176.84M
PE:-3.20
High:7.19
Open:7.00
Low:6.73
Close:7.06
Loading ...

Contineum Therapeutics Appoints Diego Miralles to Board

TIPRANKS
·
Yesterday

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Business Wire
·
Yesterday

Buy Rating for Contineum Therapeutics: Promising Pipeline and Market Opportunities

TIPRANKS
·
13 Mar

JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target

MT Newswires Live
·
13 Mar

Contineum Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Price Target $23

THOMSON REUTERS
·
13 Mar

Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%

Simply Wall St.
·
13 Mar

Contineum price target lowered to $16 from $32 at Baird

TIPRANKS
·
07 Mar

Contineum Therapeutics Inc: Cash Runway Projected Through 2027

THOMSON REUTERS
·
07 Mar

Contineum Therapeutics Q4 2024 GAAP EPS $(0.56) Misses $(0.46) Estimate

Benzinga
·
07 Mar

Press Release: Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Dow Jones
·
07 Mar

BRIEF-Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Reuters
·
05 Mar

Contineum Therapeutics Inc - Topline Data From Pipe-791 Phase 1B Trial Expected in Early 2026

THOMSON REUTERS
·
05 Mar

Contineum Therapeutics Initiates Patient Dosing in Phase 1B Chronic Pain Trial of Pipe-791

THOMSON REUTERS
·
05 Mar

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Business Wire
·
04 Mar

Contineum Therapeutics Price Target Maintained With a $31.00/Share by RBC Capital

Dow Jones
·
09 Jan

Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital

TIPRANKS
·
09 Jan